Research showed links between smoking heavily and developing genetic mutations and a greater risk for myelodysplastic ...
When people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-risk MDS, are characterized by rapid progression, severe ...
Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.
Blood disorders known as myelodysplastic syndromes/neoplasms (MDS) are difficult to diagnose – and are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and ...
The models were tested ... The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these individuals have a high mortality ...
The relationship between heteroplasmy and clonal hematopoiesis of indeterminate potential and its association with the incidence of myeloid neoplasms ... in patients with myelodysplastic syndromes ...
Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and ...
“Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic ...